Varonis Systems Insider Sold Shares Worth $4,905,444, According to a Recent SEC Filing-February 2024-www.financetom.com

Varonis Systems Insider Sold Shares Worth $4,905,444, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Varonis Systems Insider Sold Shares Worth $4,905,444, According to a Recent SEC Filing

Nov 19, 2024 8:40 PM

03:26 AM EST, 11/18/2024 (MT Newswires) -- Guy Melamed, Chief Financial Officer and Chief Operating Officer, on November 13, 2024, sold 91,345 shares in Varonis Systems ( VRNS ) for $4,905,444. Following the Form 4 filing with the SEC, Melamed has control over a total of 504,598 shares of the company, with 504,598 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1361113/000162828024048154/xslF345X05/wk-form4_1731715270.xml

Previous page： Why Is Polestar Automotive Stock Diving Today? Next page： Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Why Is Polestar Automotive Stock Diving Today?

Aug 29, 2024

Polestar Automotive Holding UK PLC ( PSNY ) shares are trading lower on Wednesday. The Swedish electric performance car brand disclosed that Michael Lohscheller will become CEO effective October 1, 2024. Lohscheller will succeed Thomas Ingenlath, who is stepping down after successfully positioning the brand for its next phase. Michael Lohscheller has formerly worked as the CEO of Opel, VinFast, and...

Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease

Aug 29, 2024

Thursday, Gain Therapeutics, Inc. ( GANX ) released results from the Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of GT-02287. The company previously announced that no discontinuations or serious adverse events were reported when the study concluded. Also Read: EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson’s Disease. The...

Box Reports Mixed Q2 Results With Modest Billings Improvement, RBC Says

Aug 29, 2024

11:12 AM EDT, 08/28/2024 (MT Newswires) -- Box (BOX) reported mixed Q2 results with modest improvements in billings as macro conditions remained stable, RBC Capital Markets said Tuesday in a report. The company reported fiscal Q2 non-GAAP earnings late Tuesday of $0.44 per diluted share on revenue of $270 million. Analysts surveyed by Capital IQ expected EPS of $0.41 on...

Dick's Sporting Goods Likely to Beat Q2 Estimates, Raise Guidance, Wedbush Says

Aug 29, 2024

11:10 AM EDT, 08/28/2024 (MT Newswires) -- Dick's Sporting Goods' (DKS) fiscal Q2 earnings are expected to top analyst estimates, but a material deceleration in trends in H2 is likely to limit a potential upside for its shares, Wedbush said in a note Wednesday. Growth is being led by the company's mid-upper income customer demographic skew, differentiated and better access...